Drug Profile


Alternative Names: L-leucine/metformin; Metformin/L-leucine; Metformin/leucine; NS-0100

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator NuSirt Biopharma
  • Class Antihyperglycaemics; Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 26 Jan 2016 NuSirt Biopharma completes a phase IIa trial in Type-2 diabetes mellitus in USA , (NCT02151461)
  • 25 Jun 2015 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus released by NuSirt Biopharma
  • 01 Oct 2014 NuSirt Biopharma initiates enrolment in a phase II extension trial for Type-2 diabetes mellitus in USA (NCT02435277)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top